Blau Farmacêutica S.A. (BVMF:BLAU3)
Brazil · Delayed Price · Currency is BRL | Market Cap | 2.47B +8.0% |
| Revenue (ttm) | 1.76B -0.2% |
| Net Income | 243.79M -9.1% |
| EPS | 1.06 -8.5% |
| Shares Out | 230.98M |
| PE Ratio | 10.12 |
| Forward PE | 7.83 |
| Dividend | 0.36 (3.32%) |
| Ex-Dividend Date | Mar 24, 2026 |
| Volume | 289,900 |
| Open | 10.83 |
| Previous Close | 10.68 |
| Day's Range | 10.69 - 11.09 |
| 52-Week Range | 8.72 - 11.84 |
| Beta | 0.33 |
| Analysts | Hold |
| Price Target | 12.55 (+14.4%) |
| Earnings Date | May 8, 2026 |
About Blau Farmacêutica
Blau Farmacêutica S.A., a pharmaceutical company provides drug products in Brazil, Argentina, Chile, Colombia, Uruguay, Ecuador, Peru, and the United States. Its products cover various areas, such as immunology, hematology, oncology, nephrology, infectology, and anesthesiology. The company offers uterine stimulator, antirheumatic, anaesthetics, antibiotics, feminine health care, biopharmaceuticals, oncologicals, hospital products, antivirals and antiretrovirals, biológicos, acid pump inhibitor, hemoderivatives, antithrombotic, and thrombolytics... [Read more]
Full Company ProfileFinancial Performance
In 2025, Blau Farmacêutica's revenue was 1.70 billion, a decrease of -2.96% compared to the previous year's 1.75 billion. Earnings were 294.96 million, an increase of 35.80%.
Financial StatementsNews
Blau Farmacêutica Earnings Call Transcript: Q1 2026
Revenue grew 17% year-over-year with margin expansion and zero leverage, driven by strong public and private channel performance and robust product launches. New production lines and pipeline approvals are expected to accelerate growth, with EBITDA margin set to improve further.
Blau Farmacêutica Earnings release: Q1 2026
Blau Farmacêutica released its Q1 2026 earnings on May 8, 2026, summarizing the period's financial results.
Blau Farmacêutica Slides: Q1 2026
Blau Farmacêutica has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 8, 2026.
Blau Farmacêutica Slides: Corporate presentation
Blau Farmacêutica has posted slides in relation to its latest quarterly earnings report, which was published on April 7, 2026.
Blau Farmacêutica Earnings Call Transcript: Q4 2025
2025 saw strategic divestment, record investments in biotech, and improved margins despite a 3% revenue drop. Net income rose 39%, and new launches plus expanded capacity set the stage for stronger, less volatile growth in 2026.
Blau Farmacêutica Earnings release: Q4 2025
Blau Farmacêutica released its Q4 2025 earnings on March 18, 2026, summarizing the period's financial results.
Blau Farmacêutica Slides: Q4 2025
Blau Farmacêutica has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 18, 2026.
Blau Farmacêutica Earnings Call Transcript: Q3 2025
Revenue and gross margin remained strong, with net income up 52% year-over-year. Capacity constraints limited growth, but major expansions and new product launches are set to drive a 70% increase in production and 60% growth in launches over the next three years.
Blau Farmacêutica Earnings release: Q3 2025
Blau Farmacêutica released its Q3 2025 earnings on November 5, 2025, summarizing the period's financial results.
Blau Farmacêutica Slides: Q3 2025
Blau Farmacêutica has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 5, 2025.
Blau Farmacêutica Earnings Call Transcript: Q2 2025
Revenue remained stable year-over-year amid capacity constraints, but gross margin and EBITDA reached post-pandemic highs. New production lines, a strong pipeline, and the Prothya exit position the company for accelerated growth and strategic investments.
Blau Farmacêutica Earnings release: Q2 2025
Blau Farmacêutica released its Q2 2025 earnings on August 6, 2025, summarizing the period's financial results.
Blau Farmacêutica Slides: Q2 2025
Blau Farmacêutica has posted slides in relation to its Q2 2025 quarterly earnings report, which was published on August 6, 2025.